Two-Drug combo shows promise for Hard-to-Treat uterine cancer

NCT ID NCT01068249

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II study tests whether the combination of letrozole (Femara) and everolimus (Afinitor) can help control advanced or recurrent endometrial cancer. The trial enrolled 42 participants whose cancer had progressed or returned. Researchers are measuring how many patients respond to treatment and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
letrozole and everolimus
What this could lead to
If this works, it could offer a new treatment option to control advanced or recurrent endometrial cancer without chemotherapy.
What could go wrong
This is a small, early-phase trial with only 42 people. The combination may not work better than existing treatments, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Morristown Memorial Hospital, Women's Cancer Center

    Morristown, New Jersey, 07962, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.